Christopher Schaber, PHD

Christopher J. Schaber has over 29 years of experience in the pharmaceutical and biotechnology industry. Dr. Schaber has been the President and Chief Executive Officer and a director of Soligenix, Inc. since August 2006. He was appointed Chairman of the Board on October 8, 2009. He also serves on the board of directors of the Biotechnology Council of BioNJ since 2009 and the Alliance for Biosecurity since 2014, and has been a member of the corporate councils of both NORD and ASBMT since 2009. Prior to joining Soligenix, Dr. Schaber served from 1998 to 2006 as Executive Vice President and Chief Operating Officer of Discovery Laboratories, Inc. From 1996 to 1998, Dr. Schaber was a co-founder of Acute Therapeutics, Inc., and served as its Vice President of Regulatory Compliance and Drug Development. Prior to that, Dr. Schaber held a variety of regulatory, development and operations positions with Ohmeda PPD, The Liposome Company, Inc., and Elkins-Sinn Inc., a division of Wyeth-Ayerst.